These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 30048343)

  • 1. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
    Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
    J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
    Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
    J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
    Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
    Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.
    Shalabi H; Martin S; Yates B; Wolters PL; Kaplan C; Smith H; Sesi CR; Jess J; Toledo-Tamula MA; Struemph K; Delbrook CP; Khan OI; Mackall CL; Lee DW; Shah NN
    Neuro Oncol; 2022 Sep; 24(9):1584-1597. PubMed ID: 35148417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.
    Gust J; Finney OC; Li D; Brakke HM; Hicks RM; Futrell RB; Gamble DN; Rawlings-Rhea SD; Khalatbari HK; Ishak GE; Duncan VE; Hevner RF; Jensen MC; Park JR; Gardner RA
    Ann Neurol; 2019 Jul; 86(1):42-54. PubMed ID: 31074527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
    Schultz LM; Jeyakumar N; Kramer AM; Sahaf B; Srinagesh H; Shiraz P; Agarwal N; Hamilton M; Erickson C; Jacobs A; Moon J; Baggott C; Arai S; Bharadwaj S; Johnston LJ; Liedtke M; Lowsky R; Meyer E; Negrin R; Rezvani A; Shizuru J; Sidana S; Egeler E; Mavroukakis S; Tunuguntla R; Gkitsas-Long N; Retherford A; Brown AK; Gramstrap-Petersen AL; Ibañez RM; Feldman SA; Miklos DB; Mackall CL; Davis KL; Frank M; Ramakrishna S; Muffly L
    Leukemia; 2024 May; 38(5):963-968. PubMed ID: 38491306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
    Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD22 CAR Therapy Leads to ALL Remissions.
    Cancer Discov; 2017 Feb; 7(2):120. PubMed ID: 28069570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
    Tedesco VE; Mohan C
    J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia.
    Tan AP
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
    Tan AP
    Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
    Lichtenstein DA; Schischlik F; Shao L; Steinberg SM; Yates B; Wang HW; Wang Y; Inglefield J; Dulau-Florea A; Ceppi F; Hermida LC; Stringaris K; Dunham K; Homan P; Jailwala P; Mirazee J; Robinson W; Chisholm KM; Yuan C; Stetler-Stevenson M; Ombrello AK; Jin J; Fry TJ; Taylor N; Highfill SL; Jin P; Gardner RA; Shalabi H; Ruppin E; Stroncek DF; Shah NN
    Blood; 2021 Dec; 138(24):2469-2484. PubMed ID: 34525183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
    Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
    Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Need for standardization of cytokine profiling in CAR T cell therapy.
    Biery DN; Turicek DP; Diorio C; Schroeder BA; Shah NN
    Mol Ther; 2024 Sep; 32(9):2979-2983. PubMed ID: 38532629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.